← SynDRA
RETAGLIPTIN
SynDRA canonical compound SYN0039587 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
| Primary target(s) | DPP4 |
| Mechanism of action | dipeptidyl peptidase inhibitor |
All known targets
Mechanisms of action (all sources)
- dipeptidyl peptidase inhibitor
- DPP4 INHIBITOR
Cross-references
Synonyms
- SP2086
- SP-2086
- DPP4 inhibitors, Shanghai Hengrui Pharmaceutical Co Ltd
- SHR-1039
- SHR-1040
- DPPIV inhibitors (diabetes), Shanghai Hengrui Pharmaceutical Co Ltd
- Dipeptidyl peptidase IV inhibitors (diabetes), Shanghai Hengrui Pharmaceutical Co Ltd
- SP 2086
- UNII-328C4R3P9L
- RefChem:178964
- Retagliptin [WHO-DD]
- SCHEMBL193599
- orb1699538
- SCHEMBL30438226
- WIIAMRXFUJLYEF-SNVBAGLBSA-N
- BDBM664705
- EX-A14303
- AKOS040749286
- US20240115577, Compound 6
- FR57620
- HY-112668A
- MS-28544
- CS-0063635
- G60994
- T28520
- methyl 7-[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazine-1-carboxylate
- رتاگلیپتین
- Retagliptin hydrochloride
- UNII-7F70K4065S
- CS-0781947
- 7F70K4065S
- orb2564338
- Retagliptin (hydrochloride)
- T88355
- HY-112668B
- SCHEMBL2862766
- RefChem:202856
- Retagliptin phosphate
Look up RETAGLIPTIN in the interactive SynDRA portal →